Challenges in translating plasma proteomics from bench to bedside: Update from the NHLBI Clinical Proteomics Programs

Robert E. Gerszten, Frank Accurso, Gordon R. Bernard, Richard M. Caprioli, Eric W. Klee, George G. Klee, Iftikhar Kullo, Theresa A. Laguna, Frederick P. Roth, Marc Sabatine, Pothur Srinivas, Thomas J. Wang, Lorraine B. Ware

Research output: Contribution to journalReview articlepeer-review

62 Scopus citations


The emerging scientific field of proteomics encompasses the identification, characterization, and quantification of the protein content or proteome of whole cells, tissues, or body fluids. The potential for proteomic technologies to identify and quantify novel proteins in the plasma that can function as biomarkers of the presence or severity of clinical disease states holds great promise for clinical use. However, there are many challenges in translating plasma proteomics from bench to bedside, and relatively few plasma biomarkers have successfully transitioned from proteomic discovery to routine clinical use. Key barriers to this translation include the need for "orthogonal" biomarkers (i.e., uncorrelated with existing markers), the complexity of the proteome in biological samples, the presence of high abundance proteins such as albumin in biological samples that hinder detection of low abundance proteins, false positive associations that occur with analysis of high dimensional datasets, and the limited understanding of the effects of growth, development, and age on the normal plasma proteome. Strategies to overcome these challenges are discussed.

Original languageEnglish (US)
Pages (from-to)L16-L22
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Issue number1
StatePublished - Jul 2008


  • Protein content
  • Proteome

ASJC Scopus subject areas

  • Physiology
  • Pulmonary and Respiratory Medicine
  • Physiology (medical)
  • Cell Biology


Dive into the research topics of 'Challenges in translating plasma proteomics from bench to bedside: Update from the NHLBI Clinical Proteomics Programs'. Together they form a unique fingerprint.

Cite this